See more : Sable Resources Ltd. (SAE.V) Income Statement Analysis – Financial Results
Complete financial analysis of Sangamo Therapeutics, Inc. (SGMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sangamo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Argonaut Gold Inc. (0UIK.L) Income Statement Analysis – Financial Results
- Banpu Public Company Limited (BPFG.F) Income Statement Analysis – Financial Results
- Fulltech Co.Ltd. (6546.T) Income Statement Analysis – Financial Results
- Minbos Resources Limited (MNB.AX) Income Statement Analysis – Financial Results
- LVMH Moët Hennessy – Louis Vuitton, Société Européenne (LVMUY) Income Statement Analysis – Financial Results
Sangamo Therapeutics, Inc. (SGMO)
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.23M | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M | 36.57M | 19.39M | 39.54M | 45.87M | 24.13M | 21.66M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 3.43M | 2.20M | 2.04M | 1.15M | 632.00K |
| Cost of Revenue | 221.56M | 12.11M | 9.44M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.13M | 56.74M | 36.98M | 31.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.23M | -700.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -45.33M | 99.19M | 101.26M | -62.46M | -43.49M | -30.41M | -29.16M | -46.23M | -27.59M | -10.87M | -12.85M | -10.05M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 8.67M | 2.90M | 2.04M | 1.15M | 632.00K |
| Gross Profit Ratio | -25.72% | 89.12% | 91.47% | -52.84% | -42.46% | -36.01% | -79.75% | -238.43% | -69.78% | -23.71% | -53.23% | -46.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 252.40% | 131.82% | 100.00% | 100.00% | 100.00% |
| Research & Development | 234.06M | 249.90M | 230.82M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.20M | 56.74M | 36.98M | 31.71M | 32.10M | 33.15M | 28.98M | 31.23M | 25.56M | 21.53M | 11.42M | 11.05M | 10.19M | 13.36M | 15.51M | 11.35M | 4.30M | 4.26M | 1.70M | 628.00K |
| General & Administrative | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.26M | 3.59M | 4.16M | 4.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 663.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.92M | 3.59M | 4.16M | 4.75M | 4.57M | 1.80M | 1.24M | 797.00K | 322.00K |
| Other Expenses | 155.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 14.04M | 0.00 | 0.00 | 10.33M | 8.31M | 7.09M | 4.81M | 4.92M | 4.16M | 22.17M | 13.06M | 9.80M | 2.50M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 21.15M | 6.80M | 5.50M | 2.50M | 950.00K |
| Cost & Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 15.92M | 6.10M | 5.50M | 2.50M | 950.00K |
| Interest Income | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.00K | 81.00K | 0.00 | 2.23M | 3.22M | 2.41M | 850.00K | 620.00K | 752.00K | 1.37M | 3.19M | 3.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.19M | 12.11M | 9.44M | 5.68M | 3.93M | 2.36M | 1.50M | 997.00K | 988.00K | 549.00K | 569.00K | 660.00K | 646.00K | 676.00K | 572.00K | 523.00K | -1.87M | -686.00K | 488.00K | 1.48M | 2.17M | 2.51M | 4.31M | 5.23M | 700.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.43M | -189.17M | -173.90M | -123.87M | -101.25M | -74.79M | -54.86M | -70.68M | -45.80M | -26.23M | -26.08M | -21.54M | -35.10M | -24.18M | -18.83M | -24.85M | -24.77M | -20.73M | -13.26M | -13.38M | -9.60M | -27.89M | -11.07M | -7.25M | -3.20M | -3.46M | -1.35M | -318.00K |
| EBITDA Ratio | -49.61% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -57.38% | -110.16% | -102.51% | -347.14% | -119.85% | -86.08% | -146.39% | -273.08% | -268.65% | -505.80% | -1,017.64% | -372.82% | -247.18% | 40.80% | -211.21% | -145.45% | -169.68% | -116.75% | -50.32% |
| Operating Income | -274.01M | -201.28M | -183.34M | -129.55M | -105.18M | -77.15M | -56.36M | -72.56M | -46.86M | -26.78M | -26.71M | -22.20M | -35.82M | -24.94M | -19.40M | -25.38M | -24.77M | -20.73M | -13.75M | -14.65M | -11.77M | -31.57M | -28.44M | -12.48M | -3.90M | -3.46M | -1.35M | -318.00K |
| Operating Income Ratio | -155.48% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -58.38% | -110.66% | -102.51% | -347.14% | -119.85% | -87.45% | -156.77% | -272.27% | -262.89% | -553.46% | -1,114.07% | -456.34% | -726.80% | -582.21% | -363.62% | -177.27% | -169.68% | -116.75% | -50.32% |
| Total Other Income/Expenses | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 1.79M | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 71.00K | 81.00K | 815.00K | 1.07M | 3.29M | 2.87M | 455.00K | 832.00K | 1.34M | 1.80M | 3.19M | 0.00 | 0.00 | 3.46M | 1.35M | 318.00K |
| Income Before Tax | -262.90M | -191.85M | -177.99M | -120.78M | -95.42M | -68.89M | -54.57M | -71.67M | -46.43M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -149.18% | -172.37% | -160.79% | -102.19% | -93.16% | -81.57% | -149.23% | -369.65% | -117.42% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.07M | 429.00K | 306.00K | 345.00K | -19.60M | 8.26M | -1.50M | -14.00K | -5.72M | -683.00K | -591.00K | -660.00K | -646.00K | -676.00K | -815.00K | -1.07M | -1.42M | -2.18M | -455.00K | -832.00K | -1.34M | -1.43M | 9.87M | -3.42M | -100.00K | 3.29M | 1.40M | 308.00K |
| Net Income | -257.83M | -192.28M | -178.30M | -121.12M | -75.82M | -68.33M | -54.57M | -71.66M | -40.70M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | -9.07M | -3.80M | -3.29M | -1.40M | -308.00K |
| Net Income Ratio | -146.30% | -172.76% | -161.06% | -102.48% | -74.02% | -80.91% | -149.23% | -369.58% | -102.94% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | -264.08% | -172.73% | -161.19% | -121.53% | -48.73% |
| EPS | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| EPS Diluted | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| Weighted Avg Shares Out | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
| Weighted Avg Shares Out (Dil) | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m. Eastern Time Guggenheim I&I Spotlight Series –...
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2022 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific...
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results. “This quarter, we have continued to progress multiple programs through clinical development and demonstrated, once again, Sangamo’s track...
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2022 FINANCIAL RESULTS
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19,...
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022. The press release will...
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022. The press release will...
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Bank of America Securities Conference Date: Wednesday, May 11th at 3:00 p.m. Eastern Time RBC Global Healthcare...
Source: https://incomestatements.info
Category: Stock Reports